Bayer Reports Topline Data from P-III (OASIS 4) Study of Elinzanetant to Treat Vasomotor Symptoms (VMS) Associated with Breast Cancer Therapies

Shots:

• The P-III (OASIS 4) study assessed elinzanetant (oral, QD) vs PBO for 52wks. to treat mod. to sev. VMS caused by endocrine therapy in women (n=474) & for another 2yrs. for those with or at high risk of HR+ breast cancer
• The study achieved its 1EP of VMS severity reduction at 4 & 12wks., 2EP of reduced VMS frequency at 1wk. & sustained effects, plus improved sleep & menopause-related quality of life at 12wks. The safety remained consistent
• Elinzanetant (NK-1 & 3 antagonist) is a non-hormonal treatment for VMS caused by menopause or adj. endocrine therapy & was subjected to 4 P-III studies (OASIS 1, 2, 3 & 4). Regulatory filings are underway in the US, EU, & other markets

Ref: Bayer | Image: Bayer

Related News:- Bayer Reports the US FDA’s sNDA Acceptance of Nubeqa (Darolutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com